Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
48 results about "Gammaretrovirus" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Gammaretrovirus is a genus in the retroviridae family. Example species are the murine leukemia virus and the feline leukemia virus. They cause various sarcomas, leukemias and immune deficiencies in mammals, reptiles and birds.
Modified retroviral vectors
The present invention relates to methods and compositions for the elucidation of mammalian gene function. Specifically, the present invention relates to methods and compositions for improved mammalian complementation screening, functional inactivation of specific essential or non-essential mammalian genes, and identification of mammalian genes which are modulated in response to specific stimuli. In particular, the compositions of the present invention include, but are not limited to, replication-deficient retroviral vectors, libraries comprising such vectors, retroviral particles produced by such vectors in conjunction with retroviral packaging cell lines, integrated provirus sequences derived from the retroviral particles of the invention and circularized provirus sequences which have been excised from the integrated provirus sequences of the invention. The compositions of the present invention further include novel retroviral packaging cell lines.
Owner:COLD SPRING HARBOR LAB INC
Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site
InactiveUS7303910B2Efficient expressionIncrease rangeSsRNA viruses negative-senseFungiNucleotideNucleotide sequencing
A retroviral vector is described. The retroviral vector comprises a functional splice donor site and a functional splice acceptor site; wherein the functional splice donor site and the functional splice acceptor site flank a first nucleotide sequence of interest (“NOI”); wherein the functional splice donor site is upstream of the functional splice acceptor site; wherein the retroviral vector is derived from a retroviral pro-vector; wherein the retroviral pro-vector comprises a first nucleotide sequence (“NS”) capable of yielding the functional splice donor site and a second NS capable of yielding the functional splice acceptor site; wherein the first NS is downstream of the second NS; such that the retroviral vector is formed as a result of reverse transcription of the retroviral pro-vector.
Owner:OXFORD BIOMEDICA (UK) LTD
Generation of human embryonc stem-like cells using intronic RNA
ActiveUS20080293143A1Stable and relatively long-term effectDelivery stabilityOther foreign material introduction processesElectrical/wave energy microorganism treatmentReprogrammingMammal
This invention generally relates to a method for developing, generating and selecting human embryonic stem (hES)-like pluripotent cells using transgenic expression of intronic microRNA-like RNA agents. More particularly, the present invention relates to a method and composition for generating a non-naturally occurring intron and its intronic components capable of being processed into mir-302-like RNA molecules in mammalian cells and thus inducing certain specific gene silencing effects on differentiation-related and fate-determinant genes of the cells, resulting in reprogramming the cells into a pluripotent embryonic stem (ES)-cell-like state. The ES-like cells so obtained are strongly express hES cell markers, such as Oct3 / 4, SSEA-3 and SSEA-4, and can be guided into various tissue cell types by treating certain hormones and / or growth factors under a feeder-free cell culture condition in vitro, which may be used for transplantation and gene therapies. Therefore, the present invention offers a simple, effective and safe gene manipulation approach for not only reprogramming somatic cells into ES-like pluripotent cells but also facilitating the maintenance of pluripotent and renewal properties of ES cells under a feeder-free cell culture condition, preventing the tedious retroviral insertion of four large transcription factor genes into one single cell as used in the previous iPS methods.
Owner:MELLO BIOTECH +1
Episomal reprogramming with chemicals
ActiveUS20110104125A1Easy to adaptHigh reprogramming efficiencyBiocideNervous disorderVector elementViral vector
Methods and composition of induction of pluripotent stem cells are disclosed. For example, in certain aspects methods for generating essentially vector-free induced pluripotent stem cells with cell signaling regulators are described. Furthermore, certain aspects of the invention provide novel compositions comprising induced pluripotent stem cells essentially free of exogenous retroviral vector elements in the presence of a medium comprising signaling inhibitors. In certain aspects, feeder-free episomal reprogramming methods may be provided.
Owner:FUJIFILM CELLULAR DYNAMICS INC
Targeted biocides
InactiveUS20050014932A1Sure easyPrevent relapseBiocideAntibody mimetics/scaffoldsInnate immune systemReceptor molecule
The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as agriculture, medicine, and national defense.
Owner:IOGENETICS
Method for producing transgenic birds and fish
The present invention relates to methods for producing transgenic animals, particularly transgenic birds and fish, using retroviral constructs engineered to carry the transgene(s) of interest.
Owner:CALIFORNIA INST OF TECH
Preparation method of immortalization pig liver cell
InactiveCN1869205AProliferate fastNot tumorigenicForeign genetic material cellsBiotechnologyPork Liver
This invention relates to pork liver cell immortalities and its producing method. Procedures are showed: high live ratio fresh original pork liver cell is got by dispase-collagenase perfusion method; it is cultured for 24 hours. Then cell upper heat removing of recombination retronituse that contains SV40 big T antigen is used to infect the pork cell under condition of polybrene which concentration is 8ug / ml. Then it is medicine pressure filtrated by 500ug / ml G418 after one week, single clone cell is picked for large culture when the cell clone appears and grows to 1.0-2.0cm to get pork cell that can passage. Reinfection is done under condition of 8ug / ml polybrene. Then it is medicine pressure filtrated by 2ug / ml puromycin after one week. Single clone cell is picked for large culture when the cell clone appears and grows to 1.0-2.0cm to get immortality pork cell.
Owner:ZHEJIANG UNIV
Colorectal cancer biomarker
The invention discloses a colorectal cancer biomarker, relating to application of interferon-induced transmembrane protein 1 in inhibition of endogenous retrovirus in colorectal cancer. The hESCs of IFITM1-KO is constructed by using CRISPR / Cas9 technology so as to study the functions of IFITM1. Studies find that the IFITM1-deleted human embryonic stem cell (hESCs) is identical with IFITM1-WT in the aspects of cell proliferation, cell pluripotency, telomere length, telomerase activity and the like. The expression of human endogenous retrovirus in hESCs of IFITM1-KO increases, and expression in para-carcinoma tissue is higher than that in colorectal carcinoma tissue. ChIP-qPCR detection finds that the enrichment of H3K9me3 in hESCs of IFITM1-KO is reduced at the HERVs site. Data shows that the expression level of IFITM1 in hESCs and colorectal carcinoma is in negative correlation to HERVs expression, and the IFITM1 can inhibit the expression of HERVs by regulating epigenetic inheritance.
Owner:NANKAI UNIV
Preparation method and use of TCR gene modified CD8+T memory stem cell
InactiveCN107541498AOvercoming heterogeneityIncrease intakeMammal material medical ingredientsAntineoplastic agentsCell specificDendritic cell
The invention belongs to the technical fields of immunology and tumor therapy, and relates to a preparation method and a use of a TCR gene modified CD8+T memory stem cell. The method comprises the following steps: co-incubating a tumor antigen and an immature dendritic cell to obtain a specific tumor antigen-supported mature dendritic cell, co-culturing the specific tumor antigen-supported maturedendritic cell and a CD8+ naive T cell, and adding a stem cell differentiation inhibitor to promote the generation of a CD8+ stem cell-like memory T lymphocyte; separating the CD8+ stem cell-like memory T lymphocyte; and cloning a T cell receptor gene (TCR) for specifically identifying a specific antigenic epitope, and carrying out lentivirus packaging or retroviral vector cotransfection on an autologous CD8+ Tscm cell to in-vitro prepare a CD8+ TCR-Tscm cell specific for different tumor specific antigens. The CD8+ TCR-Tscm cell prepared by the method has the advantages of overcoming of the tumor heterogeneity, high specificity, few adverse reactions, and highly-efficient and lasting tumor preventing and treating effects.
Owner:FUDAN UNIV SHANGHAI CANCER CENT
Lentivirus based vector and vector system
InactiveUS20020123471A1Broaden spectrumEfficient infectionBiocideNervous disorderVector systemLentivirus
The present invention relates to retroviral vectors which will infect and confer efficient gene transfer to non-dividing cells including the cells of the central nervous system. The vector system of the present invention is useful as a gene transfer vehicle for gene therapy, i.e. of the central nervous system.
Owner:BAVARIAN NORDIC RES INST AS
Triple real-time fluorescent quantitative PCR (polymerase chain reaction) detection method of three simian retroviruses
InactiveCN105624332AStrong specificityIncreased sensitivityMicrobiological testing/measurementMicroorganism based processesSimian immunodeficiency viruses SIVConserved sequence
The invention discloses a triple real-time fluorescent quantitative PCR (polymerase chain reaction) detection method of three simian retroviruses. The method comprises: using conserved sequences from gene gag of simian immunodeficiency virus SIV, gene 5'LTR of Simian T-lymphotropic virus type I to synthesize their DNA fragments, designing and synthesizing three primer pairs and three probes, respectively: SIV: upper primer SI-F, lower primer SI-R and probe SI-P, SRV1: upper primer SR-F, lower primer SR-R and probe SR-P, and STLV1: upper primer ST-F, lower primer ST-R and probe ST-P, and establishing the triple real-time fluorescent quantitative PCR detection method to precisely and quantatively detect three simian retroviruses. The invention also relates to a kit for detection, having the advantages of high detection specificity, high accuracy and good sensitivity.
Owner:海南出入境检验检疫局检验检疫技术中心
Test system for determining gene toxicities
InactiveUS20040197855A1Maximize sensitivityBroad spectrumVectorsSugar derivativesFluorescenceGenotoxic Stress
The subject matter of the invention is a method which makes it possible to detect genotoxic stress in living mammalian cells by the detection of all previously documented types of DNA recombination and also of mutations in response to noxae. The detection is based on the detection of the fluorescence from intact autofluorescent proteins or of luminescence by means of intact bioluminescent enzymes or enzymes that convert chemoluminescent substrates. It is characterised by a short reaction time in the scope of hours and permits the transfer of the test system to different mammalian cells and to living experimental animals, particularly by using a retroviral vector system.
Owner:WIESMULLER LISA
Stem and progenitor cell expansion by evi, evi-like genes and setbp1
InactiveUS20090028836A1Increasing cell proliferationEfficient deliveryBiocideVirusesActivation methodPRDM16
A method of increasing cell proliferation by modulating levels of EVI and related genes. Activation of EVI-1, PRDM16, or SETBP1 can increase the proliferation rate, self renewal and / or in vitro and / or in vivo survival and / or engraftment of human cells, either in vitro or in vivo. The gene modulation can be performed by various means, including traditional cloning methods and retroviral-based gene activation methods. The method can also be used to more efficiently deliver gene-corrected cells to a patient in need of treatment.
Owner:KALLE CHRISTOF VON +2
Targeted biocides
InactiveUS20100034824A1Polypeptide with localisation/targeting motifBiocideInnate immune systemReceptor molecule
Owner:IOGENETICS +1
Reprogramming normal and cancerous human cell lines into human induced poluripotent stem cells by co-electroporation with living xenopus laevis frog oocytes
InactiveUS20110143415A1Rapid reprogrammingCell differentiationArtificial cell constructsColony morphologyGene delivery
Using electroporation, it is possible to activate the natural reprogramming potential of living Xenopus laevis oocytes and pass it on to donor cells placed with eggs in one electroporation chamber. We demonstrated that co-electroporation at 150 v / cm / 25 μF of mature oocytes with ˜105 cells / ml of suspension of various normal and cancerous human cell lines, such as bone marrow stromal cells, foreskin fibroblasts, pre-adipocytes, CD4+ T-lymphocytes, cheek cells, cervical carcinoma (HeLa) cells and breast adenocarcinoma (MCF-7) cells, reprograms donor cells into iPSc-like cells, which form colonies on irradiated MEF feeders. The iPSc-like cells generated by this study resemble human embryonic stem cells in colony morphology and expression of stem cell-associated transcription factors, including Oct3 / 4, Nanog, SOX-2, Rex-1, TRA-1-60 and SSEA-1. New method obviates the use of retroviral or lentiviral gene delivery vectors and other “non-parental” reprogramming approaches.
Owner:PAYLIAN SERGEI
Inducible protein expression system
Inducible gene expression systems and a method thereof. A first inducible gene expression system includes a first vector comprising at least one retroviral promoter and at least one factor to induce the retroviral promoter. At least one gene product is expressed in proportion to retroviral promoter induction. The method includes providing a first vector comprising at least one retroviral promoter and providing at least one factor corresponding to the retroviral promoter. The retroviral promoter is induced with the at least one factor. At least one protein is expressed based on the induction of the retroviral promoter. A second inducing expression system includes first vector means comprising at least one retroviral promoter, means for inducing the retroviral promoter, and means for expressing at least one protein based on the induction of the retroviral promoter.
Owner:WISCONSIN ALUMNI RES FOUND
A human immortalised neural precursor cell line
InactiveCN101189327ANervous system cellsForeign genetic material cellsWilms' tumorGap Junction Proteins
The present invention relates to an immortalised human neural precursor cell line, NGC-407. The cell line has been established from human foetal tissue. The cell line has been immortalised using a retroviral vector containing the v-myc oncogene. The cell line is a neural progenitor cell line capable of differentiating into to astrocytes and neurons including dopaminergic neurons. NGC-407 cells are capable of migrating to glioblastoma tumours implanted into rat brains and form gap junctions with the tumour cells. NGC-407 cells expressing a suicide gene can be be used for delivering activated prodrugs in the form of activated nucleoside analogs to tumours.
Owner:NSGENE AS
Nucleosides analogues, such as antivirals including inhibitors of retroviral reverse transcriptase and the DNA polymerase of hepatitis B virus (HBV)
InactiveCN1275983ASugar derivativesOrganic chemistry methodsReverse transcriptaseDNA Polymerase Inhibitor
A compound of the formula (I), wherein: nuc is the residue of a nucleoside analogue bonded through its single hydroxy group on the cyclic or acyclic saccharide moiety, R1 is hydroxy, amino or carboxy; optionally having esterified / amide bonded thereon; a C4-C22 saturated or unsaturated, optionally substituted fatty acid or alcohol, or an aliphatic L-amino acid; R2 is the residue of an aliphatic L-amino acid; L1 is a trifunctional linker group; L2 is absent or a difunctional linker group; and pharmaceutically acceptable salts thereof have favourable pharmacological properties and are antivirally active.
Owner:北京恩立诺医药科技发展有限公司
Episomal reprogramming with chemicals
ActiveUS9295697B2Easy to adaptHigh reprogramming efficiencyBiocideNervous disorderVector elementViral vector
Methods and composition of induction of pluripotent stem cells are disclosed. For example, in certain aspects methods for generating essentially vector-free induced pluripotent stem cells with cell signaling regulators are described. Furthermore, certain aspects of the invention provide novel compositions comprising induced pluripotent stem cells essentially free of exogenous retroviral vector elements in the presence of a medium comprising signaling inhibitors. In certain aspects, feeder-free episomal reprogramming methods may be provided.
Owner:FUJIFILM CELLULAR DYNAMICS INC
Improved eukaryotic cells for protein manufacturing and methods of making them
PendingUS20190194694A1Microbiological testing/measurementGenetically modified cellsVirus typeRetroviral infection
Disclosed are mammalian cells and mammalian cell lines that have a reduced load of remnants of past viral / retroviral infections and methods of producing and using the same.
Owner:SELEXIS SA
Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
InactiveUS20130183383A1Improve solubilityImprove bioavailabilityAntibacterial agentsBiocideSolubilityImmunodeficiency
The present invention relates to pharmaceutical compositions of calanolides, their derivatives and analogues, and process for producing the same having enhanced solubility and bioavailability for oral or parenteral administration. The invention further provides for a method of using the disclosed compositions for the treatment and prevention of retroviral diseases such as human immunodeficiency, specifically HTV-1 and mycobacterial diseases especially tuberculosis infections in mammals, particularly humans.
Owner:CRAUN RES
Generation of human embryonic stem-like cells using intronic RNA
ActiveUS9567591B2Improve accuracyImprove efficiencySugar derivativesMicrobiological testing/measurementReprogrammingGene silencing
Owner:MELLO BIOTECH +1
Lentiviral vectors pseudotyped with mutant BaEV glycoproteins
The present invention concerns a pseudotyped viral vector particle for transferring biological material into cells, wherein said vector particle comprises at least: - a chimeric envelope glycoprotein which comprises or consists in a fusion of the transmembrane and extracellular domain of a baboon endogenous retrovirus (BaEV) envelope glycoprotein and the cytoplasmic tail domain of a murine leukemia virus (MLV) envelope glycoprotein; or - a modified BaEV envelope glycoprotein wherein the cytoplasmic tail domain is devoid of the fusion inhibitory R peptide.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1
Substituted pyrazolamides and their use
Owner:AICURIS GMBH & CO KG
Cell lines with latent immunodeficiency virus and methods of use thereof
ActiveUS7232685B2VectorsGenetically modified cellsFeline immunodeficiency virusImmunodeficiency virus
The present invention provides isolated cells that comprise, integrated into the genome of the cell, a transcription-competent immunodeficiency virus or a transcription-competent immunodeficiency virus-based retroviral vector. Under basal in vitro culture conditions, the immunodeficiency virus is latent, and the expression of the latent immunodeficiency virus can be reactivated. The invention further provides methods of making a subject cell. The invention further provides screening methods for identifying agents that activate a latent immunodeficiency virus; and screening method for identifying agents that block reactivation of latent immunodeficiency virus expression in response to T cell activation signals. The invention further provides agents identified in the subject screening assays. The invention further provides methods of treating an immunodeficiency virus infection.
Owner:THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADS
Homeodomain protein code specifying progenitor cell identify and neuronal fate in the ventral neural tube
InactiveUS6955802B1Genetic material ingredientsGenetically modified cellsPrimary motor neuronGenetically engineered
Provided are genetically engineered cells comprising a neural stem cell and retroviral expression system in the neural stem cell, which is capable of expressing homeodomain transcription factor Nkx6.1 protein but does not express homeodomain transcription factor Irx3 protein or homeodomain transcription factor Nkx2.2 protein; which is capable of expressing homeodomain transcription factor Nkx6.1 protein and homeodomain transcription factor Irx3 protein; and which is capable of expressing homeodomain transcription factor Nkx2.2 protein or homeodomain transcription factor Nkx2.9 protein. Also provided are methods of generating such genetically engineered motor neurons, V2 neurons, and V3 neurons. Also provided are methods of treating subjects having a motor neuron injury or a motor neuron disease comprising implanting in injured / diseased neural tissue of the subject any of the provided genetically engineered cells, administering to such neural tissue retroviral expression systems which are capable of expressing the appropriate homeodomain protein(s), or transfecting neural stem cells with a retroviral vector, which is capable of expressing the required homeodomain transcription factor protein(s). Provided is a method of determining whether a chemical compound affects the generation of a motor neuron from a neural stem cell.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Human immortalised neural precursor cell line
The present invention relates to an immortalised human neural precursor cell line, NGC-407. The cell line has been established from human foetal tissue. The cell line has been immortalised using a retroviral vector containing the v-myc oncogene. The cell line is a neural progenitor cell line capable of differentiating into to astrocytes and neurons including dopaminergic neurons. NGC-407 cells are capable of migrating to glioblastoma tumours implanted into rat brains and form gap junctions with the tumour cells. NGC-407 cells expressing a suicide gene can be be used for delivering activated prodrugs in the form of activated nucleoside analogs to tumours.
Owner:GLORIANA THERAPEUTICS INC
Plant retroviral polynucleotides and methods for use thereof
Retroviral and retroviral-like polynucleotides, and vectors, proteins, and antibodies derived therefrom, that are useful for the introduction of genetic information into soybeans and other plant species.
Owner:LATEN HOWARD MARK
Method and means for purifying retroviral vectors
ActiveUS20170240920A1Weak affinityHigh affinityPolypeptide with localisation/targeting motifCell receptors/surface-antigens/surface-determinantsBinding domainProtein C
The present invention relates to a producer cell which expresses a tagging protein at the cell surface, such that retroviral vectors produced by the cell are tagged with the tagging protein, wherein the tagging protein comprises: i) a binding domain which binds to a capture moiety ii) a spacer; and iii) a membrane targeting domain such that, when incorporated a retroviral vector, the tagging protein facilitates purification of the retroviral vector from cellular supernatant via binding of the tagging protein to the capture moiety. The present invention also relates to a retroviral vector comprising such a producer cell-derived tagging protein.
Owner:AUTOLUS LIMIED
Identification of a novel retrovirus associated with primary sclerosing cholangitis and autoimmune hepatitis
InactiveUS6787303B1Improve bindingReduce degradationSugar derivativesMicrobiological testing/measurementCrohn's diseaseUlcerative colitis
The present invention relates first, to the identification of a retrovirus and the novel nucleotide sequences encoding a retroviral polymerase gene (POL nucleotides) associated with the existence of primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH) Crohn's disease and ulcerative colitis. The present invention further relates to methods for using the PSC associated retroviral nucleotides for the detection of PSC, AIH, Crohn's disease and ulcerative colitis in patient samples. The present invention also relates to methods for using and targeting the PSC associated retroviral POL nucleotides in gene therapy protocols for the treatment of PSC, AIH, Crohn's disease or ulcerative disease in patients in need of such treatment. The present invention further relates to diagnostic protocols and kits for the detection of PSC, AIH, Crohn's disease and ulcerative colitis in tissue samples.
Owner:ALTON OCHSNER MEDICAL FOUND
Features
- R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
Why Patsnap Eureka
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com